Real-world evidence of a novel tetravalent immunoglobulin Y effectiveness and safety in patients with the refractory Helicobacter pylori infection

Real-world evidence of a novel tetravalent immunoglobulin Y effectiveness and safety in patients with the refractory Helicobacter pylori infection

Abstract Background Refractory Helicobacter pylori (H. pylori) infection inevitably increase the difficulty of drug selection. Here, we described our experience with the use of a novel tetravalent IgY against H. pylori for the treatment of patients with refractory H. pylori infection. Methods Patien...

Full description

Bibliographic Details
Main Authors: Nan Hao, Bo Liu, Meng Zhao, Mingming Lu, Feiyi Chen, Jialu Kang, Xiaojun Tang, Yong Zhang, Chengxue Dang
Format: Article
Language:English
Published: BMC 2024-06-01
Series:BMC Infectious Diseases
Subjects:
Helicobacter pylori
Refractory
Tetravalent IgY
Eradication
Real-world
Online Access:https://doi.org/10.1186/s12879-024-09498-4

Internet

https://doi.org/10.1186/s12879-024-09498-4

Similar Items